About Nuvaira
Nuvaira is a Healthcare company based in Minneapolis (United States) founded in 2008. A catheter-based system for COPD treatment is developed and provided. Nuvaira has raised $268.91 million across 11 funding rounds from investors including USVP, Endeavour Vision and Lightstone Ventures. The company has 57 employees. Its chief executive, as recorded, is Dennis Wahr. Nuvaira offers products and services including dNerva Lung Denervation System. Its focus areas include Life Sciences, Pulmonology, Medical Devices and Therapeutic Devices. Its legal entity is NUVAIRA, INC. Its competitors include RejuvenAir, Asthmatx and D R Burton; 2 of its 3 listed competitors have raised funding.
Company details
Nuvaira was founded in 2008 in Minneapolis, United States, within the medical device sector focused on respiratory care. Operations center on the development of the Nuvaira Lung Denervation System, a catheter-based technology for chronic obstructive pulmonary disease (COPD). This system enables Targeted Lung Denervation (TLD), a procedure by which overactive airway nerves are ablated to relieve airway obstruction and support improved breathing function.
- Headquarters Minneapolis, United States
- Employees 57
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website nuvaira.com
- Social LinkedIn X Facebook YouTube
- Legal Name Nuvaira, Inc.
- Total Equity Funding$268.91M (USD)
in 11 rounds
- Latest Funding Round$35.76M (USD), Series E
Feb 2026
- InvestorsUSVP
& 12 more
- Employee Count57
Products & Services of Nuvaira
Nuvaira offers a comprehensive portfolio of products and services, including dNerva Lung Denervation System.
Catheter-based system for one-time lung treatment to reduce COPD symptoms.
Funding Insights of Nuvaira
Nuvaira has successfully raised a total of $268.91M across 11 strategic funding rounds. The most recent funding activity was a Series E round of $35.76 million completed in February 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $268.91M
- Total Rounds 11
- Last Round Series E — $35.76M
- First Round $83,136
(Apr 2009)
- Investors Count 13
Latest 10 of 11 funding rounds of Nuvaira with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2026 | $35.76M | Series E | – | – | – |
| Nov 2023 | $15.12M | Series E | – | – | – |
| Jan 2022 | $31.34M | Series E | – | – | – |
| Feb 2019 | $79M | Series E | – | USVP, Endeavour Vision | |
| Apr 2018 | $4M | Debt – Conventional | – | – | – |
| Apr 2014 | $42M | Series D | – | Vertex Growth | |
| Apr 2014 | $42M | Series D | – | – | |
| Feb 2013 | $10M | Series C | – | – | |
| Sep 2012 | $10.6M | Series B | – | Advanced Technology Ventures | |
| Sep 2010 | $3M | Series A | – | – | – |
13 investors in total: 13 institutional.
Investors in Nuvaira
Nuvaira has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include USVP, Endeavour Vision and Lightstone Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
VC firm that focuses on early stage investments in the US | usvp.com | Menlo Park, United States | ||
Endeavour Vision is focused on transformative healthcare technology investments. | endeavourvision.com | Geneva, Switzerland | ||
Venture capital fund and fund of funds focused on the life science sector | lightstonevc.com | Menlo Park, United States | ||
US venture capital investments are made across all stages. | splitrock.com | Eden Prairie, United States | ||
VC firm making investment in early stage startups in the US | atvcapital.com | Menlo Park, United States | ||
Venture capital and private equity investment firm | morgenthaler.com | Portola Valley, United States | ||
Healthcare companies are funded by Qiming, a venture capital firm. | qimingvcusa.com | Cambridge, United States | ||
| vertexventureshc.com | ||||
Early & late stage investments focused PE & VC firm | vertexgrowth.com | |||
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com |
Investor details for Nuvaira
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Nuvaira
15 people are tracked at Nuvaira (6 in leadership, 7 in board & advisors, 2 in team); the tracked headcount is 57.
| Name | Role | Group |
|---|---|---|
Dennis Wahr | CEO | Leadership |
Thomas E. Griffin | Chief Financial Officer | Leadership |
John Carline | Senior Director, Regulatory & Quality | Leadership |
Nichole Lundeen | Human Resources Director | Leadership |
Drew Hendrickson, MCSE, VC-VIP, CEH, CISSP, CISA | Director, Information Technology & Security | Leadership |
Ryan Kaveckis | Director of Research and Development | Leadership |
Jon Root | Director | Board & advisors |
Hank Plain | Director | Board & advisors |
Tim Herbert | Director | Board & advisors |
Mike Carusi | Director | Board & advisors |
Gary Rieschel | Director | Board & advisors |
Jacques Essinger | Director | Board & advisors |
Dave Van Meter | Director | Board & advisors |
Steven Sathre | Controller | Team |
Lisa Rogan Flaherty | SVP Global Market Development | Team |
Complete people profiles for Nuvaira
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Nuvaira
3 dated milestones of Nuvaira across 18 years, from founding to its latest funding, stage changes and deals.
- Founded Nuvaira is founded.
- Funding First funding round of $83K.
- Funding Latest funding round, Series E, of $35.8M.
Competitors of Nuvaira
Nuvaira has 3 listed competitors in our database, 2 of them funded. They include RejuvenAir, Asthmatx and D R Burton.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| rejuvenair.com | 2006 | Lexington, United States | $171.11M | Cryosurgical device for chronic bronchitis and COPD treatment is developed. | ||
| asthmatx.com | 2003 | Sunnyvale, United States | $50M | Bronchial thermoplasty devices are developed for adult asthma treatment. | ||
| drburtonhpi.com | 2015 | Raleigh, United States | Provides comprehensive products for positive pressure therapy in lung disease patients. |
Detailed competitors of Nuvaira
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Pulmonology
3 companies that operate in the same segment as Nuvaira (Pulmonology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | 329 | ||
Portable oxygen concentrators are supplied for respiratory therapy needs. | 2001 | Goleta, California, United States | USD 51.65 M | USD 348.67 M | 766 | |
Robotic microsurgical systems for endoscopy are developed. | 2007 | Redwood City, California, United States | USD 733.62 M | 91 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nuvaira
Complete news archive for Nuvaira
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nuvaira
Nuvaira was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Nuvaira is headquartered in Minneapolis, United States. It is registered at Minneapolis, Minnesota, United States.
Dennis Wahr is the CEO of Nuvaira, as recorded in our data.
Nuvaira is a funded company, having raised a total of $268.91M across 11 funding rounds to date. The company's 1st funding round was a Series A of $3M, raised on Apr 2009.
Nuvaira has 57 employees.
Nuvaira was founded in 2008 in Minneapolis, United States, within the medical device sector focused on respiratory care. Operations center on the development of the Nuvaira Lung Denervation System, a catheter-based technology for chronic obstructive pulmonary disease (COPD). This system enables Targeted Lung Denervation (TLD), a procedure by which overactive airway nerves are ablated to relieve airway obstruction and support improved breathing function.
Nuvaira's top competitors include RejuvenAir, Asthmatx and D R Burton.
Nuvaira offers dNerva Lung Denervation System.
Nuvaira has 13 investors. Key investors include USVP, Endeavour Vision, Lightstone Ventures, Split Rock Partners, and Advanced Technology Ventures.
Nuvaira operates through Nuvaira, Inc..